TABLE 6
FROM:
A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma
M E Burge, D Smith, C Topham, D P Jackson, D A Anthoney, F Halstead and M T Seymour
BACK TO ARTICLETable 6. Efficacy results (response rate) by phase I and II cohorts and for all assessable patients combined (n (%) (95% confidence interval))
| Phase I | Phase II | All patients | |
|---|---|---|---|
| Complete/partial response | 6 (38) (15–65) | 9 (32) (16–52) | 15 (34) (20–50) |
| Stable disease | 5 (31) (11–58) | 9 (32) (16–52) | 14 (32) (19–48) |
| Progressive disease | 5 (31) (11–58) | 10 (36) (19–56) | 15 (34) (20–50) |
| Number of assessable patients | 16 | 28 | 44 |